AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Additional_JJ Information_NN www_NN ._.
com_NN 139_CD Additional_JJ Information_NN History_NN and_CC development_NN of_IN the_DT Company_NN Directors_NNS are_VBP not_RB required_VBN to_TO retire_VB at_IN a_DT For_IN all_DT general_JJ meetings_NNS ,_, a_DT quorum_NN of_IN two_CD particular_JJ age_NN ._.
shareholders_NNS present_VBP in_IN person_NN or_CC by_IN proxy_NN is_VBZ required_VBN ._.
AstraZeneca_NNP PLC_NNP was_VBD incorporated_VBN in_IN England_NNP and_CC Wales_NNP on_IN 17_CD June_NNP 1992_CD under_IN Directors_NNS are_VBP required_VBN to_TO beneficially_RB own_VB the_DT Companies_NNS Act_NNP 1985_CD ._.
It_PRP is_VBZ a_DT public_JJ limited_JJ Ordinary_NNP Shares_NNP in_IN the_DT Company_NN of_IN an_DT Shareholders_NNS and_CC their_PRP$ duly_RB appointed_VBN company_NN domiciled_VBD in_IN the_DT UK_NNP ._.
The_DT aggregate_JJ nominal_JJ amount_NN of_IN $_$ 125_CD ._.
At_IN proxies_NNS and_CC corporate_JJ representatives_NNS are_VBP Companys_NNP registered_VBD number_NN is_VBZ 2723534_CD present_JJ ,_, this_DT means_VBZ they_PRP must_MD own_VB at_IN least_JJS entitled_VBN to_TO be_VB admitted_VBN to_TO general_JJ meetings_NNS ._.
and_CC its_PRP$ registered_JJ office_NN is_VBZ at_IN 15_CD Stanhope_NNP 500_CD shares_NNS ._.
Gate_NNP ,_, London_NNP W1K_NNP 1LN_NNP telephone_NN 44_CD Limitations_NNPS on_IN the_DT rights_NNS to_TO own_VB shares_NNS 0_CD 20 7304 5000_CD ._.
From_IN February_NNP 1993_CD until_IN Rights_NNS ,_, preferences_NNS and_CC restrictions_NNS There_EX are_VBP no_DT limitations_NNS on_IN the_DT rights_NNS to_TO own_VB April_NNP 1999_CD ,_, the_DT Company_NN was_VBD called_VBN Zeneca_NNP attaching_VBG to_TO shares_NNS shares_NNS ._.
On_IN 6_CD April_NNP 1999_CD ,_, the_DT Company_NN The_DT share_NN capital_NN of_IN the_DT Company_NN is_VBZ divided_VBN changed_VBD its_PRP$ name_NN to_TO AstraZeneca_NNP PLC._NNP ._.
into_IN 2,400,000,000_CD Ordinary_NNP Shares_NNP with_IN a_DT ShareGift_NNP nominal_JJ value_NN of_IN $_$ 0.25_CD each_DT and_CC 50,000_CD The_DT Company_NN was_VBD formed_VBN when_WRB the_DT Redeemable_JJ Preference_NN Shares_NNS with_IN a_DT AstraZeneca_NNP welcomes_VBZ and_CC values_VBZ all_DT its_PRP$ pharmaceutical_JJ ,_, agrochemical_NN and_CC specialty_NN nominal_JJ value_NN of_IN 1.00_CD each_DT ._.
The_DT rights_NNS and_CC shareholders_NNS ,_, no_DT matter_NN how_WRB many_JJ or_CC how_WRB chemical_JJ businesses_NNS of_IN Imperial_NNP Chemical_NNP restrictions_NNS attaching_VBG to_TO the_DT Redeemable_JJ few_JJ shares_NNS they_PRP own_VBP ._.
However_RB ,_, shareholders_NNS Industries_NNPS PLC_NNP were_VBD demerged_VBN in_IN 1993_CD ._.
In_IN Preference_NNP Shares_NNP differ_VBP from_IN those_DT attaching_VBG who_WP have_VBP only_RB a_DT small_JJ number_NN of_IN shares_NNS 1999_CD ,_, the_DT Company_NN sold_VBD the_DT specialty_NN to_TO Ordinary_NNP Shares_NNP as_IN follows_VBZ :_: whose_WP$ value_NN makes_VBZ it_PRP uneconomic_JJ to_TO sell_VB chemical_NN business_NN ._.
Also_RB in_IN 1999_CD ,_, the_DT them_PRP ,_, either_RB now_RB or_CC at_IN some_DT stage_NN in_IN the_DT Company_NN merged_VBD with_IN Astra_NNP AB_NNP of_IN Sweden_NNP ._.
the_DT Redeemable_NNP Preference_NNP Shares_NNP carry_VBP future_JJ ,_, may_MD wish_VB to_TO consider_VB donating_VBG them_PRP In_IN 2000_CD ,_, it_PRP demerged_VBD the_DT agrochemical_NN no_DT rights_NNS to_TO receive_VB dividends_NNS :_: to_TO charity_NN through_IN ShareGift_NNP ,_, an_DT independent_JJ business_NN and_CC merged_VBD it_PRP with_IN the_DT similar_JJ charity_NN share_NN donation_NN scheme_NN ._.
One_CD of_IN the_DT agribusiness_NN of_IN Novartis_NNP AG_NNP to_TO form_VB a_DT new_JJ the_DT holders_NNS of_IN Redeemable_JJ Preference_NN advantages_NNS of_IN the_DT scheme_NN is_VBZ that_IN there_EX is_VBZ no_DT company_NN called_VBD Syngenta_NNP AG_NNP ._.
Shares_NNS have_VBP no_DT rights_NNS to_TO receive_VB notices_NNS gain_VB or_CC loss_NN for_IN capital_NN gains_NNS tax_NN purposes_NNS on_IN of_IN ,_, attend_VB or_CC vote_VB at_IN general_JJ meetings_NNS gifts_NNS of_IN shares_NNS through_IN ShareGift_NNP and_CC it_PRP may_MD The_DT Company_NN owns_VBZ and_CC operates_VBZ numerous_JJ except_IN in_IN certain_JJ limited_JJ circumstances_NNS :_: now_RB also_RB be_VB possible_JJ to_TO obtain_VB income_NN tax_NN R&D_NNP ,_, production_NN and_CC marketing_NN facilities_NNS they_PRP have_VBP one_CD vote_NN for_IN every_DT 50,000_CD relief_NN on_IN the_DT donation_NN ._.
Its_PRP$ corporate_JJ headquarters_NNS are_VBP at_IN Redeemable_JJ Preference_NNP Shares_NNP held_VBD :_: about_IN ShareGift_NNP can_MD be_VB found_VBN on_IN its_PRP$ website_NN ,_, 15_CD Stanhope_NNP Gate_NNP ,_, London_NNP ,_, W1K_NNP 1LN_NNP and_CC its_PRP$ www_NN ._.
org_NN ,_, or_CC by_IN contacting_VBG R&D_NNP headquarters_NNS are_VBP at_IN SE-151_CD 85_CD on_IN a_DT distribution_NN of_IN assets_NNS of_IN the_DT ShareGift_NNP on_IN 020 7337 0501_CD or_CC at_IN 46_CD Sdertlje_NNP ,_, Sweden_NNP ._.
Company_NN ,_, on_IN a_DT winding-up_NN or_CC other_JJ Grosvenor_NNP Street_NNP ,_, London_NNP W1K_NNP 3HN_NNP ._.
More_JJR return_NN of_IN capital_NN subject_NN to_TO certain_JJ information_NN about_IN the_DT tax_NN position_NN on_IN gifts_NNS of_IN Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP exceptions_NNS ,_, the_DT holders_NNS of_IN Redeemable_JJ shares_NNS to_TO ShareGift_NNP can_MD be_VB obtained_VBN from_IN the_DT Preference_NNP Shares_NNP have_VBP priority_NN over_IN the_DT Inland_NNP Revenue_NN whose_WP$ website_JJ address_NN is_VBZ Objects_NNP holders_NNS of_IN Ordinary_NNP Shares_NNP to_TO receive_VB the_DT www_NN ._.
The_DT share_NN As_IN is_VBZ typical_JJ of_IN companies_NNS registered_VBN in_IN capital_NN paid_VBN up_RP on_IN those_DT shares_NNS :_: and_CC transfer_VB form_NN needed_VBN to_TO make_VB a_DT donation_NN may_MD England_NNP and_CC Wales_NNP ,_, the_DT Companys_NNP objects_NNS ,_, be_VB obtained_VBN from_IN the_DT AstraZeneca_NNP Registrar_NNP ,_, which_WDT are_VBP detailed_VBN in_IN the_DT Memorandum_NNP of_IN subject_JJ to_TO the_DT provisions_NNS of_IN the_DT Lloyds_NNP TSB_NNP Registrars_NNPS whose_WP$ address_NN can_MD be_VB Association_NNP ,_, are_VBP broad_JJ and_CC wide-ranging_JJ and_CC Companies_NNS Act_NNP 1985_CD ,_, the_DT Company_NN has_VBZ found_VBN on_IN page_NN 129_CD ._.
ShareGift_NNP is_VBZ administered_VBN include_VBP manufacturing_NN ,_, distributing_NN and_CC the_DT right_NN to_TO redeem_VB the_DT Redeemable_JJ by_IN The_DT Orr_NNP Mackintosh_NNP Foundation_NNP ,_, trading_NN pharmaceutical_JJ products_NNS ._.
Preference_NN Shares_NNS at_IN any_DT time_NN on_IN giving_VBG registered_VBN charity_NN number_NN 1052686_CD ._.
not_RB less_JJR than_IN seven_CD days_NNS written_VBN notice_NN ._.
Directors_NNS The_DT Unclaimed_NNP Assets_NNPS Register_NNP Subject_NNP to_TO certain_JJ exceptions_NNS ,_, Directors_NNS do_VBP Action_NNP necessary_JJ to_TO change_VB the_DT rights_NNS of_IN not_RB have_VB power_NN to_TO vote_VB at_IN Board_NNP Meetings_NNS on_IN shareholders_NNS AstraZeneca_NNP supplies_VBZ unclaimed_JJ dividend_NN matters_NNS in_IN which_WDT they_PRP have_VBP a_DT material_NN interest_NN ._.
In_IN order_NN to_TO vary_VB the_DT rights_NNS attached_VBN to_TO any_DT data_NNS to_TO the_DT Unclaimed_NNP Assets_NNPS Register_NNP UAR_NNP class_NN of_IN shares_NNS ,_, the_DT consent_NN in_IN writing_NN of_IN the_DT which_WDT provides_VBZ investors_NNS who_WP have_VBP lost_VBN track_NN The_DT quorum_NN for_IN meetings_NNS of_IN the_DT Board_NNP of_IN holders_NNS of_IN three_CD quarters_NNS in_IN nominal_JJ value_NN of_IN of_IN shareholdings_NNS with_IN an_DT opportunity_NN to_TO Directors_NNS is_VBZ a_DT majority_NN of_IN the_DT full_JJ Board_NNP ,_, of_IN the_DT issued_VBN shares_NNS of_IN that_DT class_NN or_CC the_DT sanction_NN search_NN the_DT UARs_NNPS database_NN of_IN unclaimed_JJ whom_WP at_IN least_JJS four_CD must_MD be_VB Non-Executive_JJ of_IN an_DT extraordinary_JJ resolution_NN passed_VBN at_IN a_DT financial_JJ assets_NNS on_IN payment_NN of_IN a_DT small_JJ ,_, fixed_JJ Directors_NNS ._.
In_IN the_DT absence_NN of_IN a_DT quorum_NN ,_, the_DT general_JJ meeting_NN of_IN such_JJ holders_NNS is_VBZ required_VBN ._.
The_DT UAR_NNP donates_VBZ part_NN of_IN the_DT search_NN fee_NN Directors_NNS do_VBP not_RB have_VB power_NN to_TO determine_VB to_TO charity_NN ._.
The_DT UAR_NNP can_MD be_VB contacted_VBN at_IN compensation_NN arrangements_NNS for_IN themselves_PRP Annual_JJ general_JJ meetings_NNS and_CC Leconfield_NNP House_NNP ,_, Curzon_NNP Street_NNP ,_, London_NNP or_CC any_DT member_NN of_IN the_DT Board_NNP ._.
extraordinary_JJ general_JJ meetings_NNS W1J_NNP 5JA_NNP and_CC at_IN www_NN ._.
Annual_JJ general_JJ meetings_NNS and_CC extraordinary_JJ The_NNP Board_NNP of_IN Directors_NNS may_MD exercise_VB all_PDT the_DT general_JJ meetings_NNS where_WRB a_DT special_JJ resolution_NN is_VBZ powers_NNS of_IN the_DT Company_NN to_TO borrow_VB money_NN ._.
to_TO be_VB passed_VBN or_CC a_DT Director_NNP is_VBZ to_TO be_VB appointed_VBN Variation_NNP of_IN these_DT borrowing_VBG powers_NNS would_MD require_VB 21_CD clear_JJ days_NNS notice_VBP to_TO shareholders_NNS ._.
require_VB the_DT passing_NN of_IN a_DT special_JJ resolution_NN of_IN All_DT other_JJ extraordinary_JJ general_JJ meetings_NNS the_DT Companys_NNPS shareholders_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Cross_NNP Reference_NNP to_TO Form_NN 20-F_JJ www_NN ._.
com_NN 140_CD Cross_NNP Reference_NNP to_TO Form_NN 20-F_JJ The_DT information_NN in_IN this_DT document_NN that_WDT is_VBZ referenced_VBN Item_NNP Page_NNP on_IN this_DT page_NN is_VBZ included_VBN in_IN the_DT Annual_JJ Report_NNP on_IN 3_CD Key_NNP Information_NNP Form_NN 20-F_NN for_IN 2002_CD 2002_CD Form_NN 20-F_NN and_CC is_VBZ filed_VBN A._NN Selected_NNP financial_JJ data_NNS with_IN the_DT Securities_NNPS and_CC Exchange_NNP Commission_NNP SEC_NNP ._.
Financial_NNP Highlights_NNS 2_CD The_DT 2002_CD Form_NN 20-F_NN is_VBZ the_DT only_JJ document_NN intended_VBN Group_NNP Financial_NNP Record_NNP 123_CD to_TO be_VB incorporated_VBN by_IN reference_NN into_IN any_DT filings_NNS by_IN Shareholder_NN Information_NN 126_CD AstraZeneca_NNP under_IN the_DT Securities_NNP Act_NNP of_IN 1933_CD ,_, as_IN D._NNP Risk_NNP factors_NNS 134_CD amended_VBN ._.
References_NNS to_TO major_JJ headings_NNS include_VBP all_DT information_NN under_IN such_JJ major_JJ headings_NNS ,_, including_VBG 4_CD Information_NN on_IN the_DT Company_NN subheadings_NNS ._.
History_NN and_CC development_NN of_IN the_DT Company_NN 139_CD only_RB the_DT information_NN contained_VBN under_IN such_JJ Note_NN 11_CD Tangible_JJ fixed_JJ assets_NNS 78_CD subheadings_NNS ._.
Graphs_NNS are_VBP not_RB included_VBN unless_IN Note_NN 26_CD Acquisitions_NNS of_IN subsidiaries_NNS and_CC purchases_NNS of_IN minority_NN interests_NNS 90_CD specifically_RB identified_VBN opposite_NN ._.
The_DT 2002_CD Form_NN 20-F_JJ Note_NN 28_CD Disposals_NNPS 91_CD has_VBZ not_RB been_VBN approved_VBN or_CC disapproved_VBN by_IN the_DT SEC_NNP B._NNP Business_NNP overview_VBD nor_CC has_VBZ the_DT SEC_NNP passed_VBD comment_NN upon_IN the_DT Operational_NNP Review_NNP 8_CD accuracy_NN or_CC adequacy_NN of_IN the_DT 2002_CD Form_NN 20-F_NN ._.
The_DT C._NNP Organisational_NNP structure_NN 2002_CD Form_NN 20-F_NN filed_VBN with_IN the_DT SEC_NNP may_MD contain_VB Directors_NNS Report_NNP Principal_NN activities_NNS 44_CD modified_VBN information_NN and_CC may_MD be_VB updated_VBN from_IN time_NN Note_NN 1_CD Composition_NN of_IN the_DT Group_NNP 65_CD to_TO time_NN ._.
Principal_NN Subsidiaries_NNS ,_, Joint_NNP Ventures_NNP and_CC Associates_NNP 112_CD D._NNP Property_NNP ,_, plants_NNS and_CC equipment_NN Operational_NNP Review_NNP Main_NNP Facilities_NNP 26_CD 5_CD Operating_NN and_CC Financial_NNP Review_NNP and_CC Prospects_NNP A-D_NNP ._.
Financial_NNP Review_NNP 30_CD 6_CD Directors_NNS ,_, Senior_NNP Management_NNP and_CC Employees_NNP A._NNP Directors_NNS and_CC senior_JJ management_NN Board_NNP of_IN Directors_NNS and_CC Officers_NNS of_IN the_DT Company_NN 6_CD B._NNP Compensation_NNP Directors_NNS Remuneration_NNP Report_NNP 49_CD C._NNP Board_NNP practices_NNS Board_NNP of_IN Directors_NNS and_CC Officers_NNS of_IN the_DT Company_NN 6_CD Directors_NNS Remuneration_NNP Report_NNP 49_CD Directors_NNS Report_NNP 44_CD D._NNP Employees_NNP Note_NN 10_CD Segment_NN information_NN ,_, employees_NNS 76_CD Directors_NNS Report_NNP Employees_NNP 47_CD E._NNP Share_NNP ownership_NN Directors_NNS Remuneration_NNP Report_NNP Directors_NNS Interests_NNS in_IN Shares_NNP 53_CD 7_CD Major_JJ Shareholders_NNS and_CC Related_NNP Party_NNP Transactions_NNS A._NN Major_NNP shareholders_NNS Shareholder_NN Information_NN Major_NNP shareholdings_NNS 128_CD B._NNP Related_NNP party_NN transactions_NNS Shareholder_NN Information_NN Related_VBN party_NN transactions_NNS 129_CD Note_NN 36_CD Statutory_NNP and_CC other_JJ information_NN 107_CD 8_CD Financial_NNP Information_NNP A._NNP Consolidated_NNP statements_NNS and_CC other_JJ financial_JJ information_NN Financial_NNP Statements_NNP excluding_VBG Directors_NNS responsibilities_NNS on_IN page_NN 56_CD and_CC Auditors_NNS opinion_NN on_IN page_NN 57_CD 58_CD B._NNP Significant_NNP changes_NNS n_VBP a_DT 9_CD The_DT Offer_NN and_CC Listing_NN A4_NN ._.
Price_NNP history_NN of_IN stock_NN listed_VBN Shareholder_NN Information_NN 126_CD C._NNP Markets_NNP Shareholder_NN Information_NN 127_CD 10_CD Additional_JJ Information_NN B._NNP Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP 139_CD C._NNP Material_NNP contracts_NNS n_VBP a_DT D._NNP Exchange_NNP controls_VBZ 131_CD E._NNP Taxation_NNP 130_CD H._NNP Documents_NNS on_IN display_NN 129_CD I._NN Subsidiary_NNP information_NN 112_CD 11_CD Quantitative_JJ and_CC Qualitative_JJ Disclosures_NNS about_IN Market_NN Risk_NNP Financial_NNP Policies_NNS Treasury_NNP 35_CD 13_CD Defaults_NNS ,_, Dividend_NN Arrearages_NNS and_CC Delinquencies_NNS n_VBP a_DT 14_CD Material_NNP Modifications_NNS to_TO the_DT Rights_NNPS of_IN Security_NNP Holders_NNS and_CC Use_NN of_IN Proceeds_NNS n_VBP a_DT 15_CD Controls_NNP and_CC Procedures_NNP Directors_NNS Report_NNP Audit_NNP Committee_NNP ,_, Internal_NNP Controls_NNP and_CC Management_NNP of_IN Risk_NNP 46_CD 18_CD Financial_NNP Statements_NNP Financial_NNP Statements_NNP excluding_VBG Directors_NNS responsibilities_NNS on_IN page_NN 56_CD and_CC Auditors_NNS opinion_NN on_IN page_NN 57 58 694617_CD Inner_NNP Covers_NNP 2_CD 19_CD 03_CD 2:51_CD pm_NN Page_NNP 1_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD www_NN ._.
com_NN Contents_NNS Key_NNP Achievements_NNP 01_CD Trade_NNP marks_NNS Trade_NNP marks_NNS of_IN the_DT AstraZeneca_NNP group_NN Financial_NNP Highlights_NNS 02_CD of_IN companies_NNS appear_VBP throughout_IN this_DT document_NN Chairmans_NNP Statement_NNP 04_CD in_IN italics_NNS ._.
AstraZeneca_NNP ,_, the_DT AstraZeneca_NNP Chief_NNP Executives_NNS Review_NNP 05_CD logotype_NN and_CC the_DT AstraZeneca_NNP symbol_NN are_VBP all_DT trade_NN marks_NNS of_IN the_DT AstraZeneca_NNP group_NN of_IN Board_NNP of_IN Directors_NNS 06_CD companies_NNS ._.
Operational_JJ Review_NNP Use_NNP of_IN terms_NNS In_IN this_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD ,_, Strategy_NNP 08_CD unless_IN the_DT context_NN otherwise_RB requires_VBZ ,_, Key_NNP Product_NNP Summary_NNP 09_CD AstraZeneca_NNP ,_, the_DT Group_NNP ,_, the_DT Company_NN ,_, Global_NNP Market_NNP Overview_NNP 10_CD we_PRP ,_, us_PRP and_CC our_PRP$ refer_VBP to_TO AstraZeneca_NNP PLC_NNP and_CC its_PRP$ consolidated_JJ entities_NNS ._.
Gastrointestinal_NNP 11_CD Cardiovascular_NNP 12_CD Cautionary_JJ statement_NN regarding_VBG forwardOncology_NNP 13_CD looking_VBG statements_NNS In_IN order_NN to_TO utilise_VB the_DT safe_JJ harbor_NN provisions_NNS of_IN Infection_NNP 14_CD the_DT US_NNP Private_NNP Securities_NNP Litigation_NNP Reform_NNP Act_NNP Respiratory_NNP and_CC Inflammation_NNP 15_CD 1995_CD ,_, we_PRP are_VBP providing_VBG the_DT following_VBG cautionary_JJ Central_NNP Nervous_NNP System_NNP 16_CD statement_NN :_: This_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD contains_VBZ certain_JJ forward-looking_JJ Pain_NNP Control_NNP 17_CD statements_NNS about_IN AstraZeneca_NNP ._.
Although_IN we_PRP Geographic_JJ Review_NNP 18_CD believe_VBP our_PRP$ expectations_NNS are_VBP based_VBN on_IN Research_NNP and_CC Development_NNP 21_CD reasonable_JJ assumptions_NNS ,_, any_DT forward-looking_JJ statements_NNS may_MD be_VB influenced_VBN by_IN factors_NNS that_WDT Development_NNP Pipeline_NNP 22_CD could_MD cause_VB actual_JJ outcomes_NNS and_CC results_NNS to_TO be_VB Commercialisation_NNP and_CC Portfolio_NNP materially_RB different_JJ from_IN those_DT predicted_VBN ._.
We_PRP Management_NNP 24_CD identify_VB the_DT forward-looking_JJ statements_NNS by_IN using_VBG Supply_NNP and_CC Manufacturing_NNP 25_CD the_DT words_NNS anticipates_VBZ ,_, believes_VBZ ,_, expects_VBZ ,_, intends_VBZ and_CC similar_JJ expressions_NNS in_IN such_JJ Other_JJ Businesses_NNS 26_CD statements_NNS ._.
These_DT forward-looking_JJ statements_NNS Main_NNP Facilities_NNP 26_CD are_VBP subject_JJ to_TO numerous_JJ risks_NNS and_CC uncertainties_NNS ._.
Intellectual_NNP Property_NNP 27_CD Important_JJ factors_NNS that_WDT could_MD cause_VB actual_JJ results_NNS to_TO differ_VB materially_RB from_IN those_DT contained_VBN in_IN Industry_NN Regulation_NN 27_CD forward-looking_NN statements_NNS ,_, certain_JJ of_IN which_WDT are_VBP Corporate_JJ Responsibility_NN 29_CD beyond_IN our_PRP$ control_NN ,_, include_VBP ,_, among_IN other_JJ Financial_NNP Review_NNP 30_CD things_NNS :_: the_DT loss_NN or_CC expiration_NN of_IN patents_NNS ,_, marketing_NN exclusivity_NN or_CC trade_NN marks_NNS :_: exchange_NN Directors_NNS Report_NNP 44_CD rate_NN fluctuations_NNS :_: the_DT risk_NN that_IN R&D_NNP will_MD not_RB yield_VB Directors_NNS Remuneration_NNP Report_NNP 49_CD new_JJ products_NNS that_WDT achieve_VBP commercial_JJ success_NN :_: the_DT impact_NN of_IN competition_NN ,_, price_NN controls_NNS and_CC price_NN reductions_NNS :_: taxation_NN risks_NNS :_: the_DT risk_NN of_IN Financial_NNP Statements_NNP substantial_JJ product_NN liability_NN claims_NNS :_: the_DT impact_NN Contents_VBZ 55_CD of_IN any_DT failure_NN by_IN third_JJ parties_NNS to_TO supply_VB materials_NNS Financial_NNP Statements_NNP and_CC Notes_NNP Relating_NNP or_CC services_NNS :_: the_DT risk_NN of_IN delay_NN to_TO new_JJ product_NN launches_NNS :_: the_DT difficulties_NNS of_IN obtaining_VBG and_CC to_TO the_DT Financial_NNP Statements_NNP 56_CD maintaining_VBG governmental_JJ approvals_NNS for_IN Principal_NN Subsidiaries_NNS ,_, Joint_NNP Ventures_NNP products_NNS :_: and_CC the_DT risk_NN of_IN environmental_JJ and_CC Associates_NNP 112_CD liabilities_NNS ._.
Additional_JJ Information_NN for_IN US_NNP Investors_NNPS 113_CD Statements_NNS of_IN competitive_JJ position_NN Group_NNP Financial_NNP Record_NNP UK_NNP GAAP_NNP 123_CD Except_IN as_IN otherwise_RB stated_VBN ,_, market_NN information_NN Group_NNP Financial_NNP Record_NNP US_NNP GAAP_NNP 125_CD in_IN this_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Shareholder_NN Information_NN 126_CD regarding_VBG the_DT position_NN of_IN our_PRP$ business_NN or_CC products_NNS relative_JJ to_TO its_PRP$ or_CC their_PRP$ competition_NN is_VBZ Risk_NNP Factors_NNP 134_CD based_VBN upon_IN published_VBN statistical_JJ data_NNS for_IN the_DT AstraZeneca_NNP Code_NNP of_IN Conduct_NNP 137_CD 12_CD months_NNS ended_VBD 30_CD September_NNP 2002_CD ,_, or_CC the_DT Additional_JJ Information_NN 139_CD month_NN of_IN November_NNP 2002_CD ,_, obtained_VBN from_IN IMS_NNP Health_NNP ,_, a_DT leading_VBG supplier_NN of_IN statistical_JJ data_NNS to_TO Cross_NNP Reference_NNP to_TO Form_NN 20-F_JJ 140_CD the_DT pharmaceutical_JJ industry_NN ._.
Except_IN as_IN otherwise_RB stated_VBN ,_, this_DT market_NN share_NN and_CC industry_NN data_NNS from_IN IMS_NNP Health_NNP has_VBZ been_VBN derived_VBN by_IN comparing_VBG our_PRP$ sales_NNS revenue_NN to_TO competitors_NNS and_CC total_JJ market_NN sales_NNS revenues_NNS for_IN that_DT period_NN ._.
Statements_NNS of_IN growth_NN rates_NNS Except_IN as_IN otherwise_RB stated_VBN ,_, growth_NN rates_NNS in_IN this_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD are_VBP given_VBN at_IN constant_JJ exchange_NN rates_NNS CER_NNP ._.
AstraZeneca_NNP website_JJ Information_NN on_IN our_PRP$ website_NN ,_, www_NN ._.
com_NN ,_, does_VBZ not_RB form_VB part_NN of_IN this_DT document_NN ._.
AstraZeneca_NNP PLC_NNP 2003_CD AstraZeneca_NNP Annual_JJ Report_NNP &_CC Form_NN 20-F_JJ 2002 694617_CD Outer_NNP Covers_NNP 2_CD 19_CD 03_CD 2:50_CD pm_NN Page_NNP 1_CD www_NN ._.
com_NN Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Registered_NNP office_NN and_CC corporate_JJ headquarters_NNS :_: AstraZeneca_NNP PLC_NNP 15_CD Stanhope_NNP Gate_NNP London_NNP W1K_NNP 1LN_NNP UK_NNP Tel_NNP :_: 44_CD 0_CD 20 7304 5000_CD Fax_NNP :_: 44_CD 0_CD 20 7304 5183_CD R&D_NNP headquarters_NN address_NN :_: AstraZeneca_NNP R&D_NNP Sdertlje_NNP SE-151_NNP 85_CD Sdertlje_NNP Sweden_NNP Tel_NNP :_: 46_CD 0_CD 8_CD 553_CD 260_CD 00_CD Fax_NN :_: 46_CD 0_CD 8_CD 553_CD 290_CD 00_CD Investor_NNP relations_NNS contacts_NNS :_: UK_NNP and_CC Sweden_NNP :_: As_IN above_IN or_CC e-mail_VB :_: investor-relations@astrazeneca_NN ._.
com_NN US_NNP :_: Were_VBD Investor_NNP Relations_NNP AstraZeneca_NNP LP_NNP 1800_CD Concord_NNP Pike_NNP PO_NNP Box_NNP 15438_CD Wilmington_NNP fide_NN 19850-5438_CD US_NNP Tel_NNP :_: 1_CD 302 886 3000_CD reporting_NN Fax_NN :_: 1_CD 302 886 2972_CD Registrar_NNP and_CC transfer_VB office_NN :_: Lloyds_NNP TSB_NNP Registrars_NNPS The_DT Causeway_NNP Worthing_NNP West_NNP Sussex_NNP BN99_NNP 6DA_NNP UK_NNP Tel_NNP in_IN the_DT UK_NNP :_: 0870 600 3956_CD Tel_NNP outside_IN the_DT UK_NNP :_: 44_CD 0_CD 121 433 8000_CD Swedish_JJ securities_NNS registration_NN center_NN :_: VPC_NNP AB_NNP PO_NNP Box_NNP 7822_CD SE-103_NNP 97_CD Stockholm_NNP Sweden_NNP Tel_NNP :_: 46_CD 0_CD 8_CD 402_CD 9000_CD US_NNP depositary_NN :_: JPMorgan_NNP Chase_NNP Bank_NNP PO_NNP Box_NNP 43013_CD Providence_NNP RI_NNP 02940-3013_CD US_NNP Tel_NNP toll_NN free_JJ in_IN the_DT US_NNP :_: 888 697 8018_CD Tel_NNP :_: 1_CD 781 575 4328_CD
